OctoPlus N.V.

OctoPlus N.V. OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it will receive an additional € 2 million under the terms of its bridge financing, which was announced on 28 March. The payment is made by the Company's co-development partner in Locteron®, Biolex Therapeutics, Inc. The additional bridge financing will enable OctoPlus to secure one of the longer term financing options currently under negotiation.

OctoPlus N.V. OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces that today's Extraordinary General Meeting of Shareholders has approved an extension of the period for preparation of the Company's annual accounts for the year 2007 with a maximum of 6 months, until 30 November 2008.